clinical trial · NCT04981561
Safety and Tolerability of Zelquistinel in Normal Human Volunteers
Syndeio Biosciences, Inc·phase1·completed·n = 68
Major Depressive DisorderzelquistinelPlacebo
brief summary
To evaluate the safety and tolerability of single ascending doses of zelquistinel in normal human volunteers
started
Dec 9, 2016
primary completion
Dec 21, 2017
completion
Dec 21, 2017
last updated
Mar 12, 2026
detailed description
Single ascending dose (SAD), double-blind placebo-controlled study in normal human volunteers.
Secondary objectives:
To evaluate the pharmacokinetics (PK) and eeg biomarker of target engagement of zelquistinel following increasing single doses of zelquistinel.
Zelquistinel or Placebo: Dose/Mode of Administration: Single dose; oral
official title
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AGN-241751 After Oral Administration in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol